[Updated, 4:36 p.m.] Sanofi, which has worked with Principia Biopharma for the past three years to develop a new multiple sclerosis treatment that penetrates into the brain, is set to buy its partner in a $3.68 billion deal to advance the development of that drug and other autoimmune compounds in the pipeline. Under financial terms … Continue reading “Sanofi Reaches $3.68B Deal to Buy Principia and Partnered MS Drug”
Advisory Body Backs MesoBlast Therapy for Transplant Complication
An FDA advisory committee Thursday voted 9-1 to recommend that the agency approve a stem cell therapy developed by MesoBlast as a treatment for acute graft-versus-host disease (aGVHD) in children. The panel weighed the need for a new way to address the potentially fatal condition against shortcomings of the clinical trial the Australian biotech conducted … Continue reading “Advisory Body Backs MesoBlast Therapy for Transplant Complication”
CureVac’s IPO Hauls In $213M as Key mRNA COVID-19 Vaccine Test Nears
CureVac is playing catch-up to its messenger RNA (mRNA) peers in the race to develop a COVID-19 vaccine, but the company contends its technology could offer dosing advantages, and it now has $213 million in IPO cash to fund the human tests that could support that claim. On Friday, CureVac (NASDAQ: [[ticker:CVAC]]) sold more than … Continue reading “CureVac’s IPO Hauls In $213M as Key mRNA COVID-19 Vaccine Test Nears”
Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More
The road of drug development is rife with detours and disappointments but Seres Therapeutics showed this week that course corrections can work. Four years after its microbiome therapy failed in a mid-stage study, the company reported early positive data from a pivotal test of its treatment for a type of gut infection. The results are … Continue reading “Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More”
With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor
[Updated 8/13/2020, 3:19 p.m.] Duchenne muscular dystrophy (DMD) patients whose disease is characterized by a particular genetic mutation now have a new treatment option following the FDA’s Wednesday approval of a drug developed by NS Pharma. DMD is a genetic disorder that leaves patients unable to produce dystrophin, a protein key to muscle function. NS … Continue reading “With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor”
Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia
Two California biotechs have teamed up with LianBio, a new company launched earlier this week by hedge fund Perceptive Advisors, as part of deals that expand their reach into China as partners of the fledgling Shanghai-based firm. LianBio is getting the rights to develop and commercialize in Asia certain drugs from the pipelines of Brisbane, … Continue reading “Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia”
F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections
Fungal infections might not immediately come to mind as rare diseases, but growing resistance to older drugs means that patients who develop these infections have limited treatment options. Biotech company F2G aims to give these patients another choice. As the startup looks ahead to late-stage testing of its lead drug candidate, it has raised $60.8 … Continue reading “F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections”
Pfizer’s Bourla: There’s Coronavirus Vaccine Pressure, But It’s Not Political
Pfizer Inc. CEO Albert Bourla said he doesn’t worry about political pressure to bring potentially the first coronavirus vaccine to market, but can’t escape feeling the weight of the world on his shoulders. Bourla’s company is among the leaders in developing a vaccine that could ease the strain of the global pandemic that has caused … Continue reading “Pfizer’s Bourla: There’s Coronavirus Vaccine Pressure, But It’s Not Political”
Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup
Ligand Pharmaceuticals plans to acquire recombinant protein therapeutics maker Pfenex for $438 million, the companies announced Monday. The larger company agreed to pay $12 per share for Pfenex (NYSE American: [[ticker:PFNX]])—a 57 percent premium to its closing price Monday. San Diego-based Ligand (NASDAQ: [[ticker:LGND]]) generates revenue from licensing deals and royalties paid by pharmaceutical companies … Continue reading “Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup”
Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy
Bayer has been building up its women’s health drug pipeline by striking deals and on Tuesday the pharmaceutical giant unveiled its latest one: $425 million up front for KaNDy Therapeutics, a biotech whose experimental menopause drug is projected as a blockbuster seller. KaNDy’s small molecule drug, NT-814, is in development as a treatment for common … Continue reading “Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy”
Roche Gut Disease Drug Produces Mixed Results in Late-Stage Trials
Results from four studies within a major Roche-run clinical trials program of an investigational gut disease drug have muddled the antibody’s path forward after its performance proved mixed. The company has been studying etrolizumab, an antibody designed to block two members of a family of proteins called integrins, as a potential treatment for the two … Continue reading “Roche Gut Disease Drug Produces Mixed Results in Late-Stage Trials”
Seres Sets Sights on FDA After C. Diff Microbiome Therapy Scores in Phase 3
[Updated 12:37 p.m.] An experimental Seres Therapeutics capsule of live bacteria has met the goals of a pivotal study evaluating it as a treatment for a type of recurrent gut infection, preliminary results the company says put it on track for an FDA submission—potentially the first-ever application for a microbiome therapy. Seres (NASDAQ: [[ticker:MCRB]]) reported … Continue reading “Seres Sets Sights on FDA After C. Diff Microbiome Therapy Scores in Phase 3”
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
The FDA on Friday approved a new spinal muscular atrophy drug that patients can take at home. Risdiplam (Evrysdi) is a liquid medicine intended for daily use that was developed by Roche subsidiary Genentech in partnership with the SMA Foundation and South Plainfield, NJ-based PTC Therapeutics (NASDAQ: [[ticker:PTCT]]). Regulators OK’d the drug, intended for daily … Continue reading “FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy”
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
AbbVie has terminated a research partnership with Editas Medicines, returning to the biotech rights to an experimental gene-editing treatment. It’s the second genetic medicines alliance the pharmaceutical company exited this week. The Editas therapy, EDIT-101, is in Phase 1 testing as a treatment for a rare, inherited form of blindness called Leber congenital amaurosis type … Continue reading “AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact”
Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More
The novel coronavirus has driven the pharmaceutical industry to upend its research priorities. Big Pharma companies are focusing on vaccine development and a slew of biotechs are testing compounds, previously intended for a wide range of indications, as potential COVID-19 treatments. This week saw another major development brought on by industry efforts to adjust to … Continue reading “Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More”
Moderna, Pfizer Protocols May Make COVID Vaccines Hard to Compare
It will be difficult to compare Moderna, Inc. and Pfizer Inc.’s coronavirus vaccines based on their Phase 3 study designs, some vaccines experts said. “Both trials appeared to be well designed,” based on publicly available information, said Ira Longini, co-director of the Center for Statistics and Quantitative Infectious Diseases Emerging Pathogens Institute at the University … Continue reading “Moderna, Pfizer Protocols May Make COVID Vaccines Hard to Compare”
GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod
Patients with advanced multiple myeloma have a new treatment option with the FDA’s approval of a GlaxoSmithKline drug that targets B-cell maturation antigen, a protein found on the surface of cancerous plasma cells. The agency OK’d the London-based pharma giant’s cancer drug, belantamab mafodotin (Blenrep), based on the results of a study in which patients … Continue reading “GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod”
G1 Vets Launch Arc Therapeutics to Take on New Cancer Target
Three early employees of G1 Therapeutics have launched a new oncology-focused company and raised $6 million to move a preclinical program licensed from their former employer into the clinic. The startup, Research Triangle Park, NC-based Arc Therapeutics, is headed by Patrick Roberts (pictured above), who most recently served as the head of translational medicine at … Continue reading “G1 Vets Launch Arc Therapeutics to Take on New Cancer Target”
Biogen to Pay Denali $1B to Partner on Parkinson’s Drug & Other Neuro Meds
Denali Therapeutics has selected a brain-penetrating Parkinson’s disease drug candidate to advance to late-stage testing, and Biogen is paying $1 billion to kick off a partnership on that compound and potentially others. According to terms of the deal announced Thursday, the companies will co-develop the small molecule, dubbed DNL151. Biogen (NASDAQ: [[ticker:BIIB]]) also gains options … Continue reading “Biogen to Pay Denali $1B to Partner on Parkinson’s Drug & Other Neuro Meds”
MeiraGTx Names Immunovant’s Zeldin as Its Chief Medical Officer
Robert Zeldin has joined gene therapy developer MeiraGTx (NASDAQ: [[ticker:MGTX]]) as its chief medical officer. Most recently he held the same role at Immunovant (NASDAQ: [[ticker:IMVT]]). Prior Zeldin served as CMO at Acceleron Pharma (NASDAQ: [[ticker:XLRN]]) and at Ablynx. His experience also includes time at Stallergenes, Novartis (NYSE: [[ticker:NVS]]), and Merck, as well as a … Continue reading “MeiraGTx Names Immunovant’s Zeldin as Its Chief Medical Officer”
IgGenix Grabs $10M to Advance Antibody Treatments for Allergies
About six months after the FDA approved the first treatment for peanut allergy, a new biotech, IgGenix, has raised $10 million to discover antibodies that could address that and other common allergies. The six-person startup, which is based out of the Johnson & Johnson (NYSE: [[ticker:JNJ]]) JLABS incubator in South San Francisco, raised the Series … Continue reading “IgGenix Grabs $10M to Advance Antibody Treatments for Allergies”
As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up
Telemedicine giant Teladoc Health is buying health technology company Livongo Health in an $18.5 billion cash and stock deal that comes as the COVID-19 pandemic drives patients to seek ways to manage their health from home. Teladoc (NYSE: [[ticker:TDOC]]) provides “virtual healthcare services” that give patients the ability to visit with a doctor remotely. Most … Continue reading “As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up”
GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology
One of the challenges facing cell therapy developers is collecting enough cells to produce a viable treatment. It’s a particularly pronounced problem for therapies employing regulatory T cells (Tregs), a type of immune cell that’s relatively scarce in the blood, says GentiBio CEO Adel Nada. Some biotech companies are developing Treg cell therapies from a … Continue reading “GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology”
Black Diamond Makes Fang Ni’s Chief Business Officer Job Permanent
Black Diamond Therapeutics (NASDAQ: [[ticker:BDTX]]) has appointed Fang Ni to serve as its chief business officer. Ni has held the role on an interim basis since the company emerged from stealth in late 2018. Ni was most recently a principal and member of the investment team at Versant Ventures, which incubated Black Diamond before launching it … Continue reading “Black Diamond Makes Fang Ni’s Chief Business Officer Job Permanent”
Aspen Neuroscience Chief Scientific Officer Loring to Step Down
Jeanne Loring, a co-founder of Aspen Neuroscience, is stepping down from her role as its chief scientific officer. The La Jolla, CA-based company said Loring—professor emeritus at the Scripps Research Institute, where her work on the genomics of induced pluripotent stem cells laid the foundation for the company’s launch—will become a special advisor to the … Continue reading “Aspen Neuroscience Chief Scientific Officer Loring to Step Down”
Prometheus Taps Conatus’s Marshall as Its Chief Financial Officer
Prometheus Biosciences has appointed Keith Marshall its chief financial officer. Marshall most recently served as chief operating officer and CFO at Conatus Pharmaceuticals, which earlier this year merged with Histogen (NASDAQ: [[ticker:HSTO]]). Before Conatus, Marshall was CFO and head of corporate development at Flagship Pioneering spinout Torque Therapeutics, since renamed Repertoire Immune Medicines. Marshall started … Continue reading “Prometheus Taps Conatus’s Marshall as Its Chief Financial Officer”
Still Stuck on Adhesion Issues, FDA Rejects DBV’s Peanut Allergy Patch
A skin patch developed by DBV Technologies to desensitize peanut allergy sufferers to the allergen over time has been rejected by the FDA, which says the French company needs to change its design and run another clinical trial testing the modified version if it wants the treatment reviewed again. DBV (NASDAQ: [[ticker:DBVT]]), which has its … Continue reading “Still Stuck on Adhesion Issues, FDA Rejects DBV’s Peanut Allergy Patch”
CymaBay PBC Drug Hits Phase 3 Goals With Signs of Side Effect Advantage
CymaBay Therapeutics’ investigational drug seladelpar succeeded in a late-stage trial in patients with primary biliary cholangitis (PBC), producing results that suggest it could have a key side effect advantage compared to a drug currently used to treat the rare liver disease. Patients with PBC, which damages the bile ducts of the liver, are initially treated … Continue reading “CymaBay PBC Drug Hits Phase 3 Goals With Signs of Side Effect Advantage”
AbbVie Walks From Voyager R&D Pact Spanning Alzheimer’s, Parkinson’s
A partnership between Voyager Therapeutics and AbbVie developing gene therapies for Alzheimer’s and Parkinson’s disease has ended without a drug for either disease reaching human testing. Voyager (NASDAQ: [[ticker:VYGR]]) announced the termination of the research pact after market close Monday. The Cambridge, MA-based biotech is keeping full rights to its technology for using engineered viruses … Continue reading “AbbVie Walks From Voyager R&D Pact Spanning Alzheimer’s, Parkinson’s”
Legend Biotech CEO Xu Resigns, GenScript’s Zhang Named Successor
Yuan Xu, the CEO of Legend Biotech (NASDAQ: [[ticker:LEGN]]) for the past two years, has resigned for “personal reasons,” the company announced Sunday. No other details were given. She has also stepped down from the Somerset, NJ, company’s board of directors. Frank Zhang, chairman of Legend’s board and CEO of GenScript, the biotech’s largest shareholder, … Continue reading “Legend Biotech CEO Xu Resigns, GenScript’s Zhang Named Successor”
Bluebird’s Susanna High Jumps to Dyne for Chief Operating Officer Role
Dyne Therapeutics has appointed Susanna High to serve as its chief operating officer, the same position she held most recently at Bluebird Bio (NASDAQ: [[ticker:BLUE]]). High’s experience also includes senior roles at Alynlam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]) and Millennium Pharmaceuticals. Last year, Cambridge, MA-based Dyne raised $50 million in Series A financing to support the development … Continue reading “Bluebird’s Susanna High Jumps to Dyne for Chief Operating Officer Role”
MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T
A MorphoSys antibody drug developed for diffuse large B-cell lymphoma (DLBCL) has won FDA approval, providing an alternative to cumbersome and risky CAR-T therapies to treat the cancer. The late Friday approval for the drug, tafasitamab (Monjuvi), covers adults whose DLBCL has relapsed or has not responded to an earlier treatment. MorphoSys (NASDAQ: [[ticker:MOR]]), a … Continue reading “MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T”
Kymera Therapeutics Unveils IPO Pitch for Protein Degradation
Kymera Therapeutics has a pipeline of preclinical drug candidates that use an experimental approach to get rid of disease-causing proteins and it’s now looking to tap the public markets to finance tests of the technology in humans. In paperwork submitted to the Securities and Exchange Commission on Friday, Kymera set a $100 million goal for … Continue reading “Kymera Therapeutics Unveils IPO Pitch for Protein Degradation”
AnaptysBio Appoints Paul Lizzul as Its Chief Medical Officer
Paul Lizzul has joined AnaptysBio (NASDAQ: [[ticker:ANAB]]) as the company’s chief medical officer. He succeeds Marco Londei, who held the roles of CMO and chief development officer at AnaptysBio until earlier this year, when he joined Dutch biotech Gadeta as CEO. Lizzul most recently served a short stint at Amgen (NASDAQ: [[ticker:AMGN]]) as global development … Continue reading “AnaptysBio Appoints Paul Lizzul as Its Chief Medical Officer”
Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More
The biotech IPO market is buzzing but Cerevel Therapeutics is showing that there’s more than one path to the public markets. This week the neuroscience drug developer reached a deal to merge with publicly traded Arya Sciences Acquisition Corp II. If you’ve never heard of Arya (NASDAQ: [[ticker:ARYBU]]), it’s a shell company that Perceptive Advisors … Continue reading “Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More”
Novartis Pays $75M to Get Hands on Sangamo’s Zinc Fingers for Drug R&D
Another biopharma has signed up to use Sangamo Therapeutics’ gene editing technology to develop therapies that can address disease by heightening or depressing a gene’s activity level. Sangamo on Thursday announced that Novartis (NYSE: [[ticker:NVS]]) had agreed to shell out $75 million up front to leverage the biotech’s genome regulation technology to treat certain neurodevelopmental … Continue reading “Novartis Pays $75M to Get Hands on Sangamo’s Zinc Fingers for Drug R&D”
Arcutis Taps Verrica’s Burnett to Succeed Retiring Chief Medical Officer
Patrick Burnett is joining Arcutis Biotherapeutics (NASDAQ: [[ticker:ARQT]]) as its chief medical officer following the retirement of Howard Welgus, who has held the role since the company’s founding in 2016. Burnett was most recently CMO at dermatology therapeutics developer Verrica Pharmaceuticals (NASDAQ: [[ticker:VRCA]]), whose investigational topical therapy for molluscum contagiosum was rejected by the FDA earlier this month. … Continue reading “Arcutis Taps Verrica’s Burnett to Succeed Retiring Chief Medical Officer”
AlloVir’s IPO Raises $276M to Test Cell Therapies in Transplant Patients
AlloVir is the latest biotech company to go public, raising about $276.3 million to pull its cell therapies off the shelf and run multiple clinical trials testing them in stem cell and organ transplant patients. On Thursday, Cambridge, MA-based AlloVir (NASDAQ: [[ticker:ALVR]]) priced its offering of 16.25 million shares at $17 apiece, the midpoint of its … Continue reading “AlloVir’s IPO Raises $276M to Test Cell Therapies in Transplant Patients”
Amid Boom Days for Biotech, Inhibrx Lines Up Another IPO Effort
Public investors are betting big on biotechs, and Inhibrx is looking to capitalize on the industry’s recent resurgence of initial public offerings. The La Jolla, CA-based company, which is developing drugs for cancer and a rare respiratory disease, has again applied for a listing on the Nasdaq, a filing that comes more than a year … Continue reading “Amid Boom Days for Biotech, Inhibrx Lines Up Another IPO Effort”
Roche Pays $120M for Rights to UCB’s Tau-Targeting Alzheimer’s Drug
As the Alzheimer’s disease world continues to closely follow the development of therapies that break up clumps of beta amyloid on patients’ brains, Roche is placing a bet on another approach via a deal that secures rights to a clinical-stage UCB compound that targets tau, another protein associated with the neurodegenerative disorder. According to terms … Continue reading “Roche Pays $120M for Rights to UCB’s Tau-Targeting Alzheimer’s Drug”
2020 National Xconomy Awards Finalists Announced
After receiving and reviewing nearly 600 entries spanning 10 award categories, Xconomy is thrilled to announce the 2020 Xconomy National Awards Finalists. Since 2017, the mission of Xconomy’s annual awards programs has been to provide the industry a moment to pause, recognize, and honor the very best the life sciences has to offer – the … Continue reading “2020 National Xconomy Awards Finalists Announced”
Omega Therapeutics Lands $85M to Tap Into “Control Room” of Biology
The promise of gene therapies and gene-editing drugs is a long-lasting treatment that’s potentially a cure. But making permanent genetic changes means any accompanying problems could be long-lasting as well, says Omega Therapeutics CEO Mahesh Karande. Omega is developing technology that takes a more nuanced approach to genomic medicine. Instead of fixing or replacing faulty … Continue reading “Omega Therapeutics Lands $85M to Tap Into “Control Room” of Biology”
Nura Bio Debuts With $73M and Plan to Develop “Neuroprotective” Drugs
Damage to axons, the slender tendrils through which nerve cells communicate, is an early indication of several neurological diseases. Nura Bio, which formed around new research into a mechanism underlying axonal degeneration, made its public debut Wednesday with a $73 million financing round and a chief executive who has experience shepherding multiple drug development programs … Continue reading “Nura Bio Debuts With $73M and Plan to Develop “Neuroprotective” Drugs”
Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test
Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to evaluate its CancerSEEK test in a registrational study. Many cancers grow silently, and once malignant cells are discovered a patient’s prognosis … Continue reading “Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test”
Pfizer, BioNTech Choose Full Spike Protein for Pivotal Vaccine Test
Pfizer and BioNTech’s COVID-19 vaccine research started with multiple approaches—four shots on the messenger RNA goal. The partners have narrowed their choices to one for pivotal testing, and that candidate takes the same tack as other companies trying to address the novel coronavirus. BNT162b2, the vaccine candidate that Pfizer (NYSE: [[ticker:PFE]]) and BioNTech (NASDAQ: [[ticker:BNTX]]) … Continue reading “Pfizer, BioNTech Choose Full Spike Protein for Pivotal Vaccine Test”
Telehealth Firm AristaMD Adds $24M to Link Primary Docs With Specialists
Telemedicine isn’t just another way to connect patients with doctors. AristaMD has carved out a niche in connecting doctors with, well, other doctors. The San Diego-based telehealth company’s software links primary care physicians and medical specialists through virtual consultations, communication that is intended to reduce healthcare costs by slimming down the number of referrals made … Continue reading “Telehealth Firm AristaMD Adds $24M to Link Primary Docs With Specialists”
AstraZeneca to Pay $1B to Team Up With Daiichi Sankyo Again in Cancer
AstraZeneca’s partnership with Daiichi Sankyo led to FDA approval of an antibody cancer drug late last year. Now the British pharmaceutical giant is paying $1 billion up front to join forces on another antibody drug addressing a different cancer target. The deal announced Monday calls for AstraZeneca (NYSE: [[ticker:AZN]]) to share in the development and, … Continue reading “AstraZeneca to Pay $1B to Team Up With Daiichi Sankyo Again in Cancer”
Avidity Biosciences Appoints Alnylam’s Jae Kim as Chief Medical Officer
Avidity Biosciences (NASDAQ: [[ticker:RNA]]) has added Jae Kim to its C-suite as chief medical officer. Kim most recently served as vice president of clinical development at Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]). His prior experience includes roles at MyoKardia (NASDAQ: [[ticker:MYOK]]) and Amgen (NASDAQ: [[ticker:AMGN]]). San Diego-based Avidity, which raised a $100 million Series C financing round … Continue reading “Avidity Biosciences Appoints Alnylam’s Jae Kim as Chief Medical Officer”
Clinical Trial Diversity Isn’t Just a Moral Issue–It’s a Scientific Imperative
The lack of diversity in clinical trials is a serious problem that’s persisted for decades. Black Americans—who make up 20 percent of US multiple myeloma patients and are twice as likely to be diagnosed—have only accounted for 4.5 percent of participants in multiple myeloma trials since 2003. Asian Americans—who make up nearly 6 percent of … Continue reading “Clinical Trial Diversity Isn’t Just a Moral Issue–It’s a Scientific Imperative”
Gilead Gets Another CAR-T Approval, This Time for Mantle Cell Lymphoma
The FDA on Friday approved a Gilead Sciences drug developed for treating mantle cell lymphoma, paving the way for the company to commercialize its second cancer cell therapy. Approval for the drug, brexucabtagene autoleucel (Tecartus), covers patients whose cancer has relapsed or has not responded to earlier treatments. Gilead (NASDAQ: [[ticker:GILD]]) added the therapy to … Continue reading “Gilead Gets Another CAR-T Approval, This Time for Mantle Cell Lymphoma”